ViewsML Raises $4.9 Million for AI-Based Virtual Tissue Staining
The seed funding will support the commercialization of a platform designed to generate biomarker insights from pathology images without laboratory staining.
Read MorePosted by CLP Edit Staff | Apr 20, 2026 | Anatomic Pathology, Company News, Digital Pathology |
The seed funding will support the commercialization of a platform designed to generate biomarker insights from pathology images without laboratory staining.
Read MorePosted by CLP Edit Staff | Apr 20, 2026 | Analytical Software Systems, Lung Cancer |
AI integrated into molecular profiling workflows identified misclassified lung cancer cases, highlighting its potential role in improving diagnostic accuracy in clinical labs.
Read MorePosted by CLP Edit Staff | Apr 17, 2026 | Cancer, Lung Cancer, Molecular Diagnostics |
CellCarta has secured exclusive global rights to deploy Biofidelity’s Aspyre Lung assay in lung cancer clinical trials, streamlining genomic testing for trial sponsors and reducing reliance on multiple vendors.
Read MorePosted by CLP Edit Staff | Apr 16, 2026 | Anatomic Pathology, Cancer, Digital Pathology |
ViewsML will present research on its AI-powered virtual immunohistochemistry platform at AACR 2026, highlighting biomarker detection from routine H&E slides without traditional staining.
Read MorePosted by CLP Edit Staff | Apr 15, 2026 | Cancer, Company News, Molecular Diagnostics |
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
Read More